Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma

Table 1 Clinicopathological features of 12 FNH lesions and data of immunohistochemistry, clonality and LOH assays

Case numbers	Age (yr)/gender	Lesion codes	Lesion sizes (cm)	Ki-67-LI (%)	p53-LI (%)	Clonality by XCIA	No. of LOH
01	40/F	011	5.0	1.6	0	PC2	0
02	30/F	02	2.5	0.5	0	PC2	0
		03	7.0	0.8	0	PC2	0
03	22/M	043	5.2	0.7	0	NT	0
04	44/M	051	1.2	0.5	0	NT	0
05	31/F	061	4.7	0.3	0	PC2	0
06	43/F	07	3.2	1.0	0	PC2	NT
07	44/F	081	2.0	0.8	0	PC4	NT
08	53/F	095	4.8	1.0	0	PC2	NT
09	23/F	101,5	4.5	1.2	0	PC4	NT
10	46/F	111,5	5.3	0.8	0	PC3	NT
		121	1.5	0.9	0	PC4	NT

¹Some small preneoplastic foci, composed of clear cells, identified in surrounding liver parenchyma;

²Tested on phosphoglycerate kinase (PGK) locus;

³Nodules of altered hepatocytes (NAH) isolated from FNH by microdissection for LOH detection;

⁴Noninformative at PGK locus and the data obtained by the assay on androgen receptor (AR) locus;

⁵NAH isolated from FNH by microdissection for clonality assessment by XCIA. FNH: Focal nodular hyperplasia; Ki-67-LI: Ki-67 antigen-labeling indices; p53-LI: p53 protein-labeling indices by DO-7; XCIA: X-chromosomal inactivation assay; LOH: Loss of heterozygosity; F: Female; M: male; PC: Polyclonality; NT: Not tested for its origin from a male patient.